scabies
Conditions
Interventions
Prepare the Ivermectin whole body bath solution by melting a half tablet of Stromectol&
reg
3mg per 10 liters of hot water (in which baby bath agent is added). This solution is used for partial body bathing. Partial body bath test is conducted five times
two of them are for investigating soaking time
two of them are for investigating bath agent
one of them is for identifying the effect of elapsed time after bathing.
Sponsors
Tokyo University of Science
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Healthy and over age of 20 2) Have written consent on subjects' free will after being completely explained about this study
Exclusion criteria
Exclusion criteria: 1) The patient who has an obstacle in the barrier of the skin according to a skin disorder 2) Those who have the following diseases in the past or the present - Liver disease - The disease considered to affect a test result by a doctor in attendance in addition to this, or the disease considered that medication of ivermectin brings about a disadvantage 3) The superfluous ingestion person of the coffee containing caffeine, or a drink (>8 cup / day) 4) The abuse person of medicine or alcohol 5) The addict of an illegal drug 6) The woman who offered the blood of 400mL within the man and woman who offered the blood of 200mL within four weeks before the examination or the man who offered the blood of 400mL within 12 weeks, and 16 weeks 7) Those who participated in four weeks to the clinical test using other investigational new drugs before this start of test 8) Those who have an anamnesis of hypersensitivity in the ingredient of a Stromectol® Tablets or the charge of baby purification (Pigeon, Inc.) 9) The woman, the child below 15 km who have become pregnant 10) Those whom the examination doctor in attendance judged to be unsuitable as a subject 11) Those who have used medication within a week
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effects of difference in temperature/ soaking time/ bath agent on the concentration of Ivermectin transited to horny layer | — |
Secondary
| Measure | Time frame |
|---|---|
| Identification of adverse events by examined drug | — |
Countries
Japan
Contacts
Public ContactMasayo Komoda
Tokyo University of Science Faculty of Pharmaceutical Sciences
Outcome results
None listed